These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25081690)

  • 41. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.
    Keyhani E; Muhammadnejad A; Behjati F; Sirati F; Khodadadi F; Karimlou M; Moghaddam FA; Pazhoomand R
    Asian Pac J Cancer Prev; 2013; 14(12):7651-6. PubMed ID: 24460348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Estrogen and progestogen cytosol receptors in human breast carcinoma (author's transl)].
    May-Levin F; Guerinot F; Contesso G; Delarue JC; Bohuon C
    Int J Cancer; 1977 Jun; 19(6):789-95. PubMed ID: 873643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
    Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
    Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of Bax and Bcl-2 in tumour cells and blood vessels of breast cancer and their association with angiogenesis and hormonal receptors.
    Jaafar H; Abdullah S; Murtey MD; Idris FM
    Asian Pac J Cancer Prev; 2012; 13(8):3857-62. PubMed ID: 23098483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
    Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
    Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up.
    Moatamed NA; Wu A; Sarah K; Apple SK
    J Clin Pathol; 2015 Jun; 68(6):484-7. PubMed ID: 25710705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.
    Vettuparambil A; Chirukandath R; Culas TB; Vijayan SM; Rajan G; Kuttappan SV
    World J Surg Oncol; 2015 Apr; 13():160. PubMed ID: 25899789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does Mammographic Density have an Impact on the Margin Re-excision Rate After Breast-Conserving Surgery?
    Edwards BL; Guidry CA; Larson KN; Novicoff WM; Harvey JA; Schroen AT
    Ann Surg Oncol; 2016 Mar; 23(3):782-8. PubMed ID: 26471488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
    Wang YJ; Wang N; Wang B; Qin WX; Xue CY
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan.
    Begum M; Karim S; Malik A; Khurshid R; Asif M; Salim A; Nagra SA; Zaheer A; Iqbal Z; Abuzenadah AM; Alqahtani MH; Rasool M
    Asian Pac J Cancer Prev; 2012; 13(10):5257-61. PubMed ID: 23244146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
    Ravikumar G; Ananthamurthy A
    J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.